Agilent Technologies announces strategic partnership with Pacific Laboratory Products in Australia
08 March, 2010 by Staff WritersStrategic partnership will offer best-in-class support and efficient delivery of Agilent Columns and Supplies products.
Cobra venom reveals novel neurotoxin
08 March, 2010 by Tim DeanProtein in king cobra venom could lead to development of new therapeutics or molecular probes.
BIO 2010: Marinova shares sea’s bounty
05 March, 2010 by David BinningThe sight of brown seaweed is not one that would normally have people seeing dollar signs, but for Hobart-based Marinova, its solvent-free technique for extracting the coveted element fucoidan from an introduced species of sea-flora in Tasmania has made it one of Australia’s most promising up and coming biotechs.
IVD legislation goes live amidst industry concern
04 March, 2010 by Tim DeanIn vitro diagnostics legislation has passed into law although the industry still has reservations about compliance costs.
Stirling snaps up Canadian drug manufacturing plant for a song
03 March, 2010 by Staff Writers$20 million state-of-the-art manufacturing facility acquired for $3.85 million.
Bionomics announces positive results in phase Ia trial of anti-stress drug
02 March, 2010 by Staff WritersFinal results of phase Ia trial of BNC210 announced demonstrating safety and efficacy.
HalcyGen sees success in SUBA-Itraconazole study
02 March, 2010 by Staff WritersPreliminary results look good in clinical pharmacokinetic study comparing SUBA-Itraconazole with Sporanox.
BioProspect consolidates deal with Solagran
26 February, 2010 by Staff WritersSolagran and BioProspect to develop commercialisation plan for animal health and nutrition products.
Biotech Market Spotlight: HealthLinx
24 February, 2010 by Tim DeanUPDATED: Release of OvPlex ovarian cancer test in UK sends shares soaring.
Genetic Technologies hits U.S. firms with patent infringement
17 February, 2010 by Tim DeanPatent infringement suit brought against nine U.S. biotechnology companies for use of non-coding DNA technology.
QRxPharma initiates second pivotal phase III study of MoxDuo IR Dual-Opioid for NDA submission
10 February, 2010 by Staff WritersEvaluate analgesic efficacy and safety of MoxDuo IR in patients with moderate to severe post-operative pain following total knee replacement surgery.
Living Cell Technologies swaps license for portion of US company
10 February, 2010 by Staff WritersLiving Cell Technologies received 10 per cent of US startup, CytoSolv, in exchange for technology licence.
BioProspect a step closer to commercialising natural anti-termite repellent
08 February, 2010 by Tim DeanAPVMA registers Erimophilone Oil as an active ingredient, end-user product could be available within two years.
Australian biotech market watch 05/02/10
05 February, 2010 by Tim DeanCSL, ResMed, Living Cell Technology, Mesoblast, Prima BioMed, Sirtex Medical, CathRx
Another malaria breakthrough offers potential drug target
04 February, 2010 by Tim DeanResearchers at the WEHI have identified a protein that could present an attractive drug target to prevent the parasite's spread through the blood.
